Fundraising FoxPriZm Therapeutics
1 known investors
Find your way into PriZm Therapeutics
Sign up to see every warm intro you have to PriZm Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the PriZm Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
PriZm Tx develops treatments for rare genetic disorders, with a focus on MCT8 Deficiency (AHDS), an ultra-rare condition affecting boys. Its lead candidate is a first-in-class therapy for this disorder.
Investors · 1
Related companies · 2
OupOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.
FdnaFDNA develops AI-powered diagnosis and care management tools that help parents, clinicians, and researchers identify developmental delays and rare genetic disorders early. The company serves patients, families, healthcare providers, and the pharmaceutical industry across 130+ countries using facial image analysis and genetic health risk assessment technology.
Companies working in the same space as PriZm Therapeutics.
Frequently asked questions
- What does PriZm Therapeutics do?
- PriZm Tx develops treatments for rare genetic disorders, with a focus on MCT8 Deficiency (AHDS), an ultra-rare condition affecting boys. Its lead candidate is a first-in-class therapy for this disorder.
- Who are PriZm Therapeutics's investors?
- PriZm Therapeutics's investors include The Innovation Space.